Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia

Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neu...

Full description

Saved in:
Bibliographic Details
Published in:International ophthalmology 2007-02, Vol.27 (1), p.43-44
Main Authors: Govind Babu, K, Attili, Venkata Satya Suresh, Bapsy, P P, Anupama, G
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Benzamides
Chronic myeloid leukemia
Glucocorticoids - therapeutic use
Humans
Imatinib
Imatinib Mesylate
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Male
Middle Aged
Myeloid leukemia
Neuritis
Optic neuritis
Optic Neuritis - chemically induced
Optic Neuritis - drug therapy
Piperazines - adverse effects
Piperazines - therapeutic use
Prednisolone - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Side effects
Treatment Outcome
Vision Disorders - chemically induced
Vision Disorders - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imatinib is presently the commonest prescribes drug for patients of chronic myelogenous leukemia (CML) in chronic phase (CP) worldwide. Its ocular side effects are little known. Optic neuritis caused by this drug has not been reported (Medline search). We describe perhaps the first case of optic neuritis caused by this drug.
ISSN:0165-5701
1573-2630
DOI:10.1007/s10792-007-9038-9